Use of proliferation signal inhibitors in the management of post-transplant malignancies - Clinical guidance

Nephrology Dialysis Transplantation

Volumn 22, Issue SUPPL. 1, 2007, Pages

  Campistol, Josep M ^a   Albanell, Joan ^b   Arns, Wolfgang ^c   Boletis, Ioannis ^d   Dantal, Jacques ^e   de Fijter, J W ^f   Mortensen, Svend Aage ^g   Neumayer, Hans Hellmut ^h   Øyen, Ole ⁱ   Pascual, Julio ^j   Pohanka, Erich ^k   Schena, F Paolo ^l   Serón, Daniel ^m   Sparacino, Vito ⁿ   Chapman, Jeremy R ^o,p  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^d LAIKO GENERAL HOSPITAL   (Greece)

^e NANTES UNIVERSITY HOSPITAL   (France)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g Rigshospitalet   (Denmark)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ OSLO UNIVERSITY HOSPITAL   (Norway)

^j HOSPITAL RAMÓN Y CAJAL   (Spain)

^k MEDICAL UNIVERSITY OF VIENNA   (Austria)

^l POLICLINICO   (Italy)

^m HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

ⁿ Renal Unit   (Italy)

^o UNIVERSITY OF SYDNEY   (Australia)

^p WESTMEAD HOSPITAL   (Australia)

more..

Author keywords

Immunosuppression; Malignancy; Proliferation signal inhibitors mTOR inhibitors; Renal transplant

Indexed keywords

AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VINCRISTINE; CALCINEURIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; PROTEIN KINASE;

ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INCIDENCE; CANCER REGRESSION; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN DISEASE; SOLID TUMOR; SURVIVAL TIME; DRUG ANTAGONISM; DRUG EFFECT; NEOPLASM; REVIEW;

CALCINEURIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; NEOPLASMS; PROTEIN KINASES; SIGNAL TRANSDUCTION; SIROLIMUS;

EID: 34250183832     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfm090     Document Type: Article

References (57)

1. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001; 16: 1545-1549
2. ANZDATA. Australia and New Zealand Dialysis and Transplant Registry, 2006. Available at: http://www.anzdata.org.au/. Accessed January 2007
3. Chapman J, Webster A. In: Excell L, McDonald S, eds. Cancer. ANZDATA Registry Report 2004. Australia and New Zealand Dialysis and Transplant Registry, Adelaide, South Australia: 100-103
4. Birkeland SA, Storm HH, Lamm LU et al. Cancer risk after renal transplantation in the Nordic countries, 1964-1986. Int J Cancer 1995; 60: 183-189
5. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905-913
6. Dantal J, Hourmont M, Cantarovich D et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomized comparison of two cyclosporine regimens. Lancet 1998; 351: 623-628
7. Vivarelli M, Bellusci R, Cucchetti A et al. Low recurrence of hepatocellular carcinoma after liver transplantation: Better patient selection or lower immunosuppression? Transplantation 2002; 74: 1746-1751
8. Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. J Am Soc Nephrol 2004; 15: 1582-1588
9. Dantal J, Pohanka E. Malignancies in renal transplantation: An unmet medical need. Nephrol Dial Transplant 2007; 22 [Suppl 1]: I4-i10
10. Gutiérrez-Dalmau Á, Campistol JM. The role of proliferation signal inhibitors in post-transplant malignancies. Nephrol Dial Transplant 2007; 22 [Suppl 1]:i11-i16
11. Gutierrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: A systematic review. Drugs (in press)
12. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Post-transplant de novo malignancies in renal transplant recipients: The past and present. Transplant Int 2006; 19: 607-620
13. Guba M, von Breitenbuch P, Steinbauer M et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor. Nature Med 2002; 8: 128-135
14. Luan FL, Hojo M, Maluccio M et al. Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 1565-1572
15. Boulay A, Zumstein-Mecker S, Stephan C et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64: 252-261
16. Majewski M, Korecka M, Joergensen J et al. Immunosuppressive TOR kinase inhibitor everolimus (RAD) suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft-protecting doses. Transplantation 2003; 75: 1710-1717
17. Xu Q, Simpson SE, Scialla TJ, Bagg A, Carroll M. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003; 102: 972-980
18. Majumder PK, Febbo PG, Bikoff R et al. MTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia. through regulation of apoptopic and HIF-1-dependent pathways. Nat Med 2004; 10: 594-580
19. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889
20. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004; 18: 446-449
21. Campistol JM, Eris J, Oberbauer R et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation. J Am Soc Nephrol 2006; 17: 581-589
22. Pascual J. Concentration-controlled everolimus (Certican®): Combination with reduced dose calcineurin inhibitors. Transplantation 2005; 79: S76-S79
23. Vítko Š, Tedesco H, Eris J et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626-635
24. Oberbauer R, Segoloni G, Campistol JM et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 2005; 18: 22-28
25. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 1993; 55: 742-747
26. Khariwala SS, Kjaergaard J, Lorenz R, Van Lente F, Shu S, Strome M. Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII). Laryngoscope 2006; 116: 814-820
27. Stallone G, Schena A, Infante B et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323
28. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: A successful treatment for post-transplantation Kaposi's sarcoma. Transplantation 2004; 77: 760-762
29. Lebbe C, Euvrard S, Barrou B et al. Sirolimus conversion for patients with posttransplant Kaposi's sarcoma. Am J Transplant 2006; 6: 2164-2168
30. Amato RJ, Misellati A, Khan M, Chiang S. A Phase II trial of RAD001 in patients (Pts) with metastatic renal cell carcinoma (MRCC). J Clin Oncol 2006; 24 [Suppl 18]: Abstract 4530
31. Reddy GK, Mughal TI, Rini BI. Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma. Clin Genitourin Cancer 2006; 5: 110-113
32. Cullis B, D'Souza R, McCullagh P et al. Sirolimus-induced remission of posttransplantation lymphoproliferative disorder. Am J Kidney Dis 2006; 47: E67-72
33. Pascual J. Post-transplant lymphoproliferative disorder - the potential of proliferation signal inhibitors. Nephrol Dial Transplant 2007; 22 [Suppl 1]: I27-i35
34. Purighalla R, Shapiro R, Jordan ML et al. Acute renal allograft rejection in patients with Epstein-Barr virus associated post-transplant lymphoproliferative disorder. Clin Transplant 1997; 11: 574-576
35. Knoop C, Kentos A, Remmelink M et al. Post-transplant lymphoproliferative disorder after lung transplantation: First-line treatment with rituximab may induce complete remission. Clin Transplant 2006; 20: 179-187
36. Oertel SH, Verschuuren E, Reinke P et al. Effect of anti-CD20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901-2906
37. Wasson S, Zafar MN, Best J, Reddy HK. Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: A single-center experience. J Cardiovasc Pharmacol Ther 2006; 11: 77-83
38. Lorenzini S, Andreone P, Gramenzi A et al. Posttransplant lymphoproliferative disorders in liver transplanted patients: A report of four cases. Transplant Proc 2006; 38: 1477-1480
39. Elstrom RL, Andreadis C, Aqui NA et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569-576
40. Garcia VD, Bonamigo Filho JL, Neumann J et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003; 16: 202-206
41. Veroux M, Puliatti C, Fiamingo P et al. Early de novo malignancies after kidney transplantation. Transplant Proc 2004; 36: 718-720
42. Kneteman NM, Oberholzer J, Al Saghier M et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl 2004; 10: 1301-1311
43. Stippel DL, Kasper HU, Schleimer K et al. Successful use of sirolimus in a patient with bulky ovarian metastasis of hepatocellular carcinoma after liver transplantation. Transplant Proc 2005; 37: 2185-2187
44. Elsharkawi M, Staib L, Henne-Bruns D, Mayer J. Complete remission of postransplant lung metastases from hepatocellular carcinoma under therapy with sirolimus and mycophenolate mofetil. Transplantation 2005; 79: 855-857
45. Tabernero J, Rojo F, Burris H et al. A Phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients with advanced solid tumors. J Clin Oncol 2005; 23: Abstract 3007
46. Lorber MI, Ponticelli C, Whelchel J et al. Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy and safety data. Clin Transplant 2005; 19: 145-152
47. Knight RJ, Villa M, Welsh M et al. Risk factors for impaired wound healing in sirolimus treated renal transplant recipients. Am J Transplant 2003; 3: 481
48. Opelz G, Döhler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2003; 4: 222-230
49. Caillard S, Dharnidharka V, Agadoa L, Bohen E, Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 1233-1243
50. Robson R, Cecka JM, Opelz G, Budde M, Sacks S. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954-2960
51. Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289-1293
52. Eberhard OK, Kliem V, Brunkhorst R. Five cases of Kaposi's sarcoma in kidney graft recipients: Possible influence of the immunosuppressive therapy. Transplantation 1999; 67: 180-184
53. Jonas S, Rayes N, Neumann U et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 1997; 80: 1141-1150
54. Glover MT, Deeks, Raftery MJ, Cunningham J, Leigh IM. Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet 1997; 349: 398
55. Marcén R, Pascual J, Tato AM et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc 2003; 35: 1714-1716
56. Shuttleworth D, Marks R, Griffin PJ, Salaman JR. Epidermal dysplasia and cyclosporine therapy in renal transplant patients: A comparison with azathioprine. Br J Dermatol 1989; 120: 551-554
57. Fernández A, Marcén R, Pascual J et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipinets with malignant neoplasia. Transplant Proc 2006; 38: 2453-2455